Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 128

1.

Should transplantation still be considered for Ph1-negative myeloproliferative neoplasms in transformation?

Ruggiu M, Cassinat B, Kiladjian JJ, Raffoux E, Giraudier S, Robin M, Itzykson R, Clappier E, Michonneau D, de Fontbrune FS, de Latour RP, Ades L, Socié G.

Biol Blood Marrow Transplant. 2020 Feb 28. pii: S1083-8791(20)30105-1. doi: 10.1016/j.bbmt.2020.02.019. [Epub ahead of print]

2.

Correction: Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment.

Caye A, Rouault-Pierre K, Strullu M, Lainey E, Abarrategi A, Fenneteau O, Arfeuille C, Osman J, Cassinat B, Pereira S, Anjos-Afonso F, Currie E, Ariza-McNaughton L, Barlogis V, Dalle JH, Baruchel A, Chomienne C, Cavé H, Bonnet D.

Leukemia. 2020 Jan 31. doi: 10.1038/s41375-020-0720-5. [Epub ahead of print]

PMID:
32005921
3.

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491.

Levy G, Carillo S, Papoular B, Cassinat B, Zini JM, Leroy E, Varghese LN, Chachoua I, Defour JP, Smith SO, Constantinescu SN.

Blood. 2020 Mar 19;135(12):948-953. doi: 10.1182/blood.2019003240.

PMID:
31978223
4.

Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations.

Pangallo J, Kiladjian JJ, Cassinat B, Renneville A, Taylor J, Polaski JT, North K, Abdel-Wahab O, Bradley RK.

Blood. 2020 Mar 26;135(13):1032-1043. doi: 10.1182/blood.2019002894.

PMID:
31961934
5.

Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment.

Caye A, Rouault-Pierre K, Strullu M, Lainey E, Abarrategi A, Fenneteau O, Arfeuille C, Osman J, Cassinat B, Pereira S, Anjos-Afonso F, Currie E, Ariza-McNaughton L, Barlogis V, Dalle JH, Baruchel A, Chomienne C, Cavé H, Bonnet D.

Leukemia. 2019 Nov 27. doi: 10.1038/s41375-019-0662-y. [Epub ahead of print] Erratum in: Leukemia. 2020 Jan 31;:.

PMID:
31776464
6.

Synergistic effects of PRIMA-1Met (APR-246) and Azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.

Maslah N, Salomao N, Drevon L, Verger E, Partouche N, Ly P, Aubin P, Naoui N, Schlageter MH, Bally C, Miekoutima E, Rahmé R, Lehmann-Che J, Ades L, Fenaux P, Cassinat B, Giraudier S.

Haematologica. 2019 Sep 5. pii: haematol.2019.218453. doi: 10.3324/haematol.2019.218453. [Epub ahead of print]

7.

Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation.

Mannina D, Gagelmann N, Badbaran A, Ditschkowski M, Bogdanov R, Robin M, Cassinat B, Heuser M, Shahswar R, Thol F, Beelen D, Kröger N.

Eur J Haematol. 2019 Dec;103(6):552-557. doi: 10.1111/ejh.13318. Epub 2019 Sep 16.

PMID:
31446640
8.

Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses.

Maslah N, Soret J, Dosquet C, Vercellino L, Belkhodja C, Schlageter MH, Cassinat B, Kiladjian JJ, Chomienne C, Giraudier S.

Haematologica. 2020 Mar;105(3):e95-e97. doi: 10.3324/haematol.2018.215582. Epub 2019 Aug 14. No abstract available.

9.

How much does 2016 WHO classification of myeloproliferative neoplasms affect the clinic?

Cassinat B, Giraudier S, Kiladjian JJ.

Expert Rev Hematol. 2019 Jul;12(7):473-476. doi: 10.1080/17474086.2019.1623019. Epub 2019 Jun 4. No abstract available.

PMID:
31161817
10.

A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases.

El Bouchtaoui M, Do Cruzeiro M, Leboeuf C, Loisel-Ferreira I, Fedronie C, Ferreira C, Ait El Far R, Ziol M, Espié M, Falgarone G, Cassinat B, Kiladjian JJ, Feugeas JP, Janin A, Bousquet G.

Clin Cancer Res. 2019 Jul 15;25(14):4504-4515. doi: 10.1158/1078-0432.CCR-18-3261. Epub 2019 Apr 19.

PMID:
31004003
11.

When hemolysis masks polycythemia vera.

Derrieux C, Jeandel R, Martin A, Dosquet C, Cassinat B, Fouillard L.

Clin Case Rep. 2019 Jan 28;7(3):438-441. doi: 10.1002/ccr3.1776. eCollection 2019 Mar.

12.

Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation.

Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B, Shahswar R, Thol F, Heuser M, Socié G, Beelen D, Triviai I, Badbaran A, Kröger N.

Blood. 2019 May 16;133(20):2233-2242. doi: 10.1182/blood-2018-12-890889. Epub 2019 Feb 13.

PMID:
30760453
13.

Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.

Jutzi JS, Basu T, Pellmann M, Kaiser S, Steinemann D, Sanders MA, Hinai ASA, Zeilemaker A, Bojtine Kovacs S, Koellerer C, Ostendorp J, Aumann K, Wang W, Raffoux E, Cassinat B, Bullinger L, Schlegelberger B, Valk PJM, Pahl HL.

Blood. 2019 Apr 18;133(16):1766-1777. doi: 10.1182/blood-2018-09-875047. Epub 2019 Feb 12.

14.

International external quality assurance of JAK2 V617F quantification.

Asp J, Skov V, Bellosillo B, Kristensen T, Lippert E, Dicker F, Schwarz J, Wojtaszewska M, Palmqvist L, Akiki S, Aggerholm A, Tolstrup Andersen M, Girodon F, Kjær L, Oppliger Leibundgut E, Pancrazzi A, Vorland M, Andrikovics H, Kralovics R, Cassinat B, Coucelo M, Eftimov A, Haslam K, Kusec R, Link-Lenczowska D, Lodé L, Matiakowska K, Naguib D, Navaglia F, Novotny GW, Percy MJ, Sudarikov A, Hermouet S, Pallisgaard N.

Ann Hematol. 2019 May;98(5):1111-1118. doi: 10.1007/s00277-018-3570-8. Epub 2018 Dec 8.

15.

Exome analysis of treatment-related AML after APL suggests secondary evolution.

Wang T, Jacoby MA, Duncavage EJ, Miller CA, Heath S, Rahme R, Fenaux P, Ades L, Renneville A, Cassinat B, Takeshita A, Asou N, Miyazaki Y, Kiyoi H, Ravandi F, Westervelt P, Wartman LD, Welch JS.

Br J Haematol. 2019 Jun;185(5):984-987. doi: 10.1111/bjh.15681. Epub 2018 Nov 22. No abstract available.

PMID:
30467844
16.

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.

Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z, Kralovics R, Gisslinger H, Grohmann-Izay B, Klade C, Chomienne C, Giraudier S, Cassinat B, Kiladjian JJ.

Blood Cancer J. 2018 Oct 4;8(10):94. doi: 10.1038/s41408-018-0133-0.

17.

Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls.

Maslah N, Verger E, Schlageter MH, Miclea JM, Kiladjian JJ, Giraudier S, Chomienne C, Cassinat B.

Ann Hematol. 2019 Jan;98(1):111-118. doi: 10.1007/s00277-018-3499-y. Epub 2018 Sep 26.

PMID:
30259120
18.

Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features.

Guadall A, Lesteven E, Letort G, Awan Toor S, Delord M, Pognant D, Brusson M, Verger E, Maslah N, Giraudier S, Larghero J, Vanneaux V, Chomienne C, El Nemer W, Cassinat B, Kiladjian JJ.

Thromb Haemost. 2018 Sep;118(9):1586-1599. doi: 10.1055/s-0038-1667015. Epub 2018 Aug 13.

PMID:
30103245
19.

Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.

Lehmann-Che J, Bally C, Letouzé E, Berthier C, Yuan H, Jollivet F, Ades L, Cassinat B, Hirsch P, Pigneux A, Mozziconacci MJ, Kogan S, Fenaux P, de Thé H.

Nat Commun. 2018 May 24;9(1):2047. doi: 10.1038/s41467-018-04384-5.

20.

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.

Renneville A, Attias P, Thomas X, Bally C, Hayette S, Farhat H, Eclache V, Marceau-Renaut A, Cassinat B, Feuillard J, Terré C, Delabesse E, Park S, Lejeune J, Chevret S, Adès L, Preudhomme C, Fenaux P.

Leukemia. 2018 Sep;32(9):2066-2069. doi: 10.1038/s41375-018-0137-6. Epub 2018 Apr 18. No abstract available.

PMID:
29740159

Supplemental Content

Loading ...
Support Center